Aristotle University Of Thessaloniki (AUTH)
Μελέτη των συσσωματωμάτων αιμοπεταλίων - μονοκυττάρων στην ιδιοπαθή αρτηριακή υπέρταση
Abstract
dc:descriptionEssential hypertension (EH) is associated with an increased incidence of arterial thrombotic complications, which is sustained by a number of factors: endothelial dysfunction, clinically detectable atherosclerosis, increased activity of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS), changes in coagulation and fibrinolysis and increased platelet activation. When platelets are activated, they aggregate with each other and with monocytes forming monocyte–platelet aggregates (MPA). Circulating MPA levels represent the most sensitive and robust marker in several clinical settings. The objective of this study was to investigate the presence of ιIncreased thrombotic tendency and factors associating with it from the early stages of EH.Therefore, we enrolled newly diagnosed and untreated patients with EH and no comorbidities (UH) and healthy normotensive controls (NT). We utilized the exercise test (Bruce protocol) to model the effect of acute blood pressure (BP) rising after intense physical activity. MPA levels were studied by flow cytometry in both groups while resting and during acute exercise. Furthermore, we studied platelet P-selectin by flow cytometry and representative markers of coagulation and fibrinolysis, TAT (thrombin-antithrombin) complex and PAI-1 (plasminogen activator inhibitor-1) using ELISA kits. Changes of these markers were also studied after 3- month antihypertensive treatment. Then, we aimed to study the presence of subclinical atherosclerosis, endothelial dysfunction and arterial stiffness while resting and during acute exercise, when possible. Subclinical atherosclerosis was detected by carotid intima-media thickness (CIMT) using ultrasound measurements and endothelial dysfunction by asymmetric dimethylarginine (ADMA) using ELISA. Arterial stiffness was measured by aortic pulse wave velocity (aPWV) using applanation tonometry. High sensitivity C-reactive protein (hsCRP) and cardiotrophin-1 were also measured by ELISA.We studied 30 UH and 15 NT. No difference was found between the two groups in the demographic, clinical and biochemical characteristics, except for blood pressure (BP) levels. All participants achieved maximal high-intensity exercise in the exercise test. In total, 17 patients received antihypertensive treatment with an angiotensin receptor blocker (valsartan 160 mg) and were re-evaluated after 3 months. Treated patients achieved adequate BP control.Regarding MPA measurements, UH showed a significant increase of circulating MPA at peak exercise compared to baseline levels (p<0.001). MPA levels remained increased at 10 and 30 minutes after peak exercise (p<0.001 και p=0.002 respectively). On the contrary, NT showed a significant increase of MPA levels only 10 minutes after peak exercise (p=0.046). Between the two groups, MPA levels were significantly higher in UH subjects than NT subjects at maximal exercise and at 10 and 30 minutes of recovery (p=0.035, p=0.020 and p=0.016). Post-treatment MPA levels increased significantly only at 10 minutes into recovery (p=0.010) and were similar to those of NT subjects.In addition, we studied platelet P-selectin levels showing no significant difference between UH and NT at rest or during exercise. Post-exercise P-selectin levels were significantly increased in both groups compared to baseline levels. Post-treatment P-selectin levels were significantly decreased compared to pre-treatment levels.Along with platelet activation, we also investigated changes in coagulation and fibrinolysis by measuring TAT and PAI-1 levels. Significantly increased TAT and PAI-1 levels were found in UH versus NT at rest (p=0.018 and p=0.030 respectively), peak exercise (p=0.028 and p=0.024) and 30 minutes later (p=0.030 και p=0.042). UH showed an increase of TAT and PAI-1 levels at peak exercise (p=0.030 και p=0.036) compared to baseline levels; while NT exhibited a significant increase only of TAT complexes at peak exercise. Post-treatment levels of TAT and PAI-1 were significantly decreased compared to pre-treatment ones at rest, maximal exercise and 30 minutes later (p=0.008, p=0.019, p=0.028 and p=0.017, p=0.020, p=0.022 respectively).In participants with adequate measurements at all time-points, we also investigated arterial stiffness changes (n=25 and n=15 for UH and NT respectively). Aortic PWV was significantly increased in UH compared to NT at all time-points (p<0.001). In UH, we also found a significant increase of aPWV at peak exercise compared to baseline that was attenuated 10 and 30 minutes later. However, no significant change was observed in the NT group. Post-treatment aPWV values were significantly decreased at all time-points (p<0.001). During exercise, treated hypertensive individuals exhibited a significant increase of aPWV only at peak exercise.Then, we aimed to detect underlying functional and structural vascular changes in our naïve population. We observed a trend toward a significant increase of cardiotrophin-1 and ADMA levels in UH versus NT. To further investigate this trend we expanded our study population using the same inclusion and exclusion criteria. In total, we studied 45 UH and 25 NT. UH showed significantly increased CIMT compared to NT (0.62 ± 0.30 mm versus 0.49 ± 0.21 and 0.59 ± 0.2 mm versus 0.47 ± 0.08 for left and right common carotid artery respectively, p<0.001). However, there were no signs of subclinical atherosclerosis (CIMT<0.9 mm). Furthermore, we also detected a significant increase of hsCRP levels in UH compared to NT (2.8 ± 1.2 versus 0.24 ± 0.6 mg/l, p<0.001). In the multivariate analysis, central pulse pressure (β=0.309, p=0.007) and aPWV (β=0.385, p=0.001) proved independent predictors of hsCRP. In addition, cardiotrophin-1 levels were significantly increased: 542.03 ± 340.32 compared to 306.61 ± 187.5 pg/ml in NT (p<0.001). Central systolic and diastolic BP levels were found to independently correlate with cardiotrophin-1 levels in the multivariate analysis (β = 0.421; p = 0.04 και β=0.728; p=0.02), after correction for day systolic and diastolic BP, aPWV and hsCRP. Lastly, UH also exhibited increased ADMA levels (0.91 ± 0.3 in UH versus 0.53 ± 0.3 μmol/l in ΝΤ, p=0.039), which were significantly associated with systolic BP (r=0.276, p=0.042), aPWV (r=0.421, p=0.031) and hsCRP (r=0,582, p=0,039) levels. Of note, we observed a significant positive association between ADMA levels and maximal MPA levels at 10 minutes after peak exercise (r=0.324, p=0.047).In conclusion, young newly-diagnosed untreated patients with EH and no clinically detectable atherosclerosis showed an exaggerated and prolonged increase of platelet activation and hypercoagulability, along with impaired fibrinolysis after acute BP rising caused by acute high-intensity exercise. Similarly, untreated hypertensives exhibited an exaggerated and prolonged increase of arterial stiffness during acute exercise. In addition, 3-month antihypertensive treatment with valsartan resulted in a significant decrease of platelet activation and hypercoagulability and improvement of the fibrinolytic and arterial stiffness response back to levels similar to NT. Regarding underlying functional and structural vascular changes, hsCRP, cardiotrophin-1 and ADMA were significantly increased and correlated with arterial stiffness indices in hypertensive patients from the early stages of the disease.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gavriilaki, Eleni
- Γαβριηλάκη, Ελένη
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38191